The Challenges of Acute Interstitial Nephritis:
Time to Standardize

Dennis G. Moledina\textsuperscript{1,2} and Mark A. Perazella\textsuperscript{1,3*}

\textsuperscript{1}Department of Internal Medicine (Nephrology), Yale School of Medicine, New Haven, CT
\textsuperscript{2}Clinical and Translational Research Accelerator, Yale University School of Medicine, Department of Medicine, New Haven, CT
\textsuperscript{3}VA Medical Center, West Haven, CT

*For all communication
Mark A. Perazella, MD
Yale University School of Medicine
New Haven, Connecticut
Email:mark.perazella@yale.edu
Acute interstitial nephritis (AIN) is a well-known cause of acute and chronic kidney disease (CKD) and is associated with progression to end-stage kidney disease (ESKD) \(^1\,^6\). Accordingly, it represents an important problem for clinicians caring for these patients. AIN is primarily an immune-mediated kidney injury triggered by use of certain medications, in particular antibiotics, PPIs, NSAIDs, and immune-checkpoint inhibitors or by autoimmune diseases such as Sjogren’s syndrome, sarcoidosis, IgG4-related tubulointerstitial disease, and TINU. In developed countries, medications are the most common cause of AIN (>70%) while the number approximates 50% in developing countries. Infectious agents are a less common cause of AIN except in developing countries.

The overall incidence of AIN in kidney biopsy registries is 2-5%, while AIN is observed in approximately 15-20% of patients with acute kidney injury (AKI) or acute kidney disease (AKD) who undergo kidney biopsy \(^1\,^3\). The actual number is likely higher as many patients with AKI/AKD don’t undergo biopsy and are presumed to have acute tubular injury (ATI). Importantly, diagnosing AIN clinically is often quite challenging, making kidney biopsy a frequent requirement to definitively confirm the diagnosis and guide therapy (Figure 1). Furthermore, delayed or missed AIN diagnosis leads to ongoing inflammation with resulting interstitial fibrosis, tubular atrophy and permanent kidney damage, which may be the explanation for CKD occurring in 40-60% of patients after an episode of AIN \(^4\,^5\). Approximately 2% of CKD is considered to be due to AIN, which is equivalent to 10 million prevalent worldwide cases. Furthermore, AIN is the primary cause of ESKD in 3-4% incident patients \(^6\). It is one of the few potentially treatable causes of AKI if identified and treated early. In view of these data, three key challenges that limit the diagnosis and management of patients suspected of having AIN are discussed.

**Clinical Diagnostic Challenges of AIN**

Since the clinical diagnosis of AIN is difficult, delayed or missed diagnosis frequently occurs. Most patients with AIN do not have any characteristic systemic symptoms or signs such as rash, fever, or flank pain \(^7\,^10\). Most often, they manifest nonspecific constitutional symptoms, symptoms of kidney failure (when advanced), or no symptoms at all. Currently available diagnostic tests, including serum and urine eosinophils, and urine sediment examination for leukocytes and leukocyte casts have poor sensitivity and specificity for AIN diagnosis. Imaging tests such as ultrasonography, CT scan, gallium scan, and PET/CT scan are also suboptimal. In retrospective analysis of 76 patients, of which 23 were considered to have AIN, renal gallium-67 uptake showed an AUC of 0.75. However, only 20 out of 76 patients were biopsied to confirm or exclude AIN and those who determined diagnostic outcome were likely not blinded to gallium-67 results \(^11\).

Thus, the diagnosis of AIN currently relies entirely on maintaining a high index of clinical suspicion for this disease and often requires confirmation by a kidney biopsy. Biopsy may not be feasible or delayed during optimization in some patients due to underlying bleeding risk \(^12\,^13\). The lack of a diagnostic biomarker for AIN and need for a kidney biopsy to establish AIN diagnosis often delays diagnosis, which is associated with permanent kidney damage. Unfortunately, delay in diagnosis and management of AIN is associated with lower recovery of kidney function \(^4\,^14\,^16\).

A potential solution to this diagnostic challenge has recently been identified. Based on the fact that CD4+ T-cells play an important role in the pathogenesis of AIN \(^17\,^19\), 12 cytokines in the Th1 (interferon-γ, IL-2, IL-12), Th2 (IL-4, IL-5, IL-13), and Th9 (IL-9) pathways, as well as other generally inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-10) were measured in the urine and plasma in patient with biopsy-proven AIN and various other diagnoses. In this prospective study, urine TNF-α and IL-9 levels were consistently higher in participants with biopsy-proved, adjudicated AIN compared with other causes of AKD \(^20\). These cytokine biomarkers were higher in AIN than ATI, glomerular diseases, and diabetic kidney disease, as well as in participants without kidney disease. Urine TNF-α and IL-9 improved discrimination for AIN diagnosis as compared with the clinical nephrologist’s pre-biopsy AIN diagnosis and a model consisting of currently available blood and urine tests. Overall, these results suggest that concomitantly elevated levels of urine TNF-α and IL-9 are specific to AIN and may be a useful biomarker to distinguish AIN from other clinical causes of AKD. Furthermore, a higher ratio of urinary M1 (pro-inflammatory) to M2 (anti-inflammatory) macrophages was shown to differentiate between AIN and other kidney pathologies \(^21\). Importantly, new insights into the pathogenesis of AIN as well its diagnosis and therapy may be garnered from this study. A recent study measured urinary retinol-binding protein/Cr in patients with immune-
checkpoint inhibitor (ICPI)-associated AKI (14/37 had biopsy-proven AIN) and 13 patients with non-ICPI-associated AKI (2/4 with biopsy-proven acute tubular injury)\textsuperscript{22}. In a subgroup of patients, urinary retinol-binding protein/Cr was statistically increased in the ICPI-AKI group vs. the ICPI-non-AIN group. All of these data offer hope for a non-invasive diagnostic test for AIN.

**Pathological Diagnostic Challenges of AIN**

Kidney biopsy with histology is considered the “gold standard” for diagnosis of AIN. However, in the absence of consensus guidelines regarding histological diagnosis of AIN, there is significant heterogeneity in reporting by pathologists. Currently, histological diagnosis of AIN is based on 2 major components. These include 1) an interstitial infiltrate consisting of lymphocytes, monocytes, macrophages, plasma cells and sometimes eosinophils, and 2) presence of tubulitis, which represents the extension/invasion of the inflammatory cells into tubules. Acute tubular injury, interstitial edema and interstitial fibrosis often may accompany AIN. Unfortunately, the presence and severity of these findings are often interpreted subjectively without a standard approach.

It is increasingly recognized that the reliability of kidney biopsy reports by a single pathologist has limitations. In a prospective observational study, we noted that a majority of adjudicating pathologists re-classified clinically reported AIN cases into non-AIN controls in a third of cases. This reclassification was lower when AIN was listed as the first diagnosis (18%) than when it was listed as 2\textsuperscript{nd} or later diagnosis (41%)\textsuperscript{20}. In addition, there was low inter-rater agreement among pathologists. We noted a low kappa for agreement for AIN diagnosis (0.35), as well as features of interstitial infiltrate (0.22), tubulitis (0.20), and eosinophils (0.39). Furthermore, an acute interstitial infiltrate is commonly associated with other diagnoses on the biopsy including ATI, diabetic kidney disease, lupus nephritis, and ANCA-associated vasculitis. It is unclear when AIN is thought to be secondary to these associated diagnoses, which would not warrant management changes directed at AIN or a separate diagnosis that would require therapeutic intervention. This poses a significant challenge for treating clinicians in making management decisions particularly if a kidney pathologist is not available on site for discussion, which is increasingly common at many centers. Clinicians in our study seemed to understand the uncertainty in histological diagnosis. Nineteen-percent of AIN diagnoses were subsequently reclassified as NOT AIN; this reclassification was lower when AIN was listed as first diagnosis (8%) than when it was listed as second or later diagnosis (29%).

Pathologists are often asked to determine if AIN is due to a drug or other etiology such as a systemic disease (Sjogren’s syndrome, sarcoidosis, IgG4 disease, TINU, etc.), infection, or idiopathic. An eosinophil-predominant infiltrate often raises the possibility of drug-induced AIN, however, several drugs do not have an eosinophilic infiltrate and non-drug causes may have eosinophils. In some cases, the histology can identify non-drug causes such as IgG4 disease (IgG4 staining plasma cells and storiform fibrosis) and sarcoidosis with lymphocyte-dominant infiltrate and non-caseating granuloma. Most important to determining etiology is an ongoing discussion of the patient’s clinical data and histological data by the nephrologist and pathologist. Unfortunately, this approach may not be common practice for many clinicians and pathologists.

There are a few solutions to the challenges with histopathological diagnosis of AIN, which at this time appears to be a suboptimal “gold standard”. First, pathologists in the NEPTUNE study improved concordance on glomerular diagnoses through an iterative adjudication process using description-based scoring system\textsuperscript{23}. Thus, it might be possible to improve the agreement among pathologists by establishing consensus criteria for AIN. Certainly such criteria exist for the histopathology in many other kidney diseases. Second, reporting of interstitial features should be undertaken in a standardized manner (e.g., percentages or percentage ranges). Terms such as mild, moderate, minimal, and severe should be avoided, as they are subjective and not helpful to the clinician. This approach would improve patient care and research by allowing comparison across centers, studies and pathologists, help develop models to diagnose AIN using interstitial features, and allow application of machine learning techniques to biopsy slides. Finally, identification of etiology specific subsets of immune cells involved in AIN may lead to improved histological diagnosis as well as guide
treatment. For example, recent studies have shown involvement of mast cells and Th17 cells in AIN, which are not routinely tested in clinical histopathology\textsuperscript{18,24}.

**Prognosis and Management Challenges of AIN**

There are no evidence-based guidelines available to aid clinicians in the management of patients with AIN. This results in a substantial variation in practice. For example, while it is accepted that withdrawal of the offending drug is the best first step after diagnosis of drug-induced AIN, prescription of corticosteroid therapy is more controversial. Observational studies of corticosteroid use in AIN show conflicting results in terms of benefit for kidney function recovery potentially indicating heterogenous treatment effects\textsuperscript{16}. It is possible that there are certain subgroups of patients with AIN who derive the most benefit from corticosteroids (e.g., those with highly active immune responses), whereas others gain little benefit and only experience treatment side effects. However, there are currently no guidelines around which patients are best suited to this therapy.

Recent data suggest that urine biomarkers may help select appropriate patients for therapy\textsuperscript{25}. In a prospective cohort of participants with biopsy-proven, adjudicated AIN, higher urine IL-9 levels were associated with lower kidney function only in patients who did not receive corticosteroid therapy\textsuperscript{25}. Corticosteroid therapy was noted to be most beneficial in the patient subgroup with higher urine IL-9 levels and higher baseline estimated GFR before the onset of AIN. These findings provide a potential framework for IL-9-guided clinical trials to test the efficacy of immunosuppressive therapy in patients with AIN. In addition, higher interstitial fibrosis is associated with lower kidney function recovery, whereas higher interstitial inflammation is associated with greater kidney function recovery\textsuperscript{25}. These findings could assist clinicians in providing a more accurate estimate of prognosis to patients with AIN. However, it remains unclear what the appropriate dose, route of delivery (oral vs. intravenous) and duration of therapy should be for patients. Thus, clinicians rely on expert opinion and local practices vary by center. In addition to corticosteroids, other agents with potential utility for AIN such as mycophenolic acid, infliximab, and other agents should undergo study in biopsy-proven AIN.

**Approach to Challenges associated with AIN**

We propose that the key diagnostic and management issues relevant to patients with AIN be the focus of basic research and clinical investigation. This area of acute tubulointerstitial disease needs evidence-based guidelines and/or expert consensus opinion to assist clinicians in their care of these patients. Focus on key aspects of clinical and histological diagnosis and management of patients suspected of having AIN is an important first step. The field sorely needs useful clinical and laboratory criteria to confirm a clinical diagnosis of AIN. In the same vein, consensus histological criteria are needed to determine a pathological diagnosis of AIN. Additionally, a consensus approach for prognosis and treatment of AIN that addresses issues of patient selection for immunosuppressive therapy, dose and duration of therapy, as well as predictors of prognosis is required. Finally, knowledge gaps and areas of needed research in each of the 3 AIN domains must be identified. **Table 1** lists areas and challenges that must be addressed.
Disclosures

D. Moledina Research Funding: NIDDK K23DK117065, R01DK12681, UH3DK114866, P30DK079310 outside submitted work; Honoraria: National Kidney Foundation, Remedy health media, British medical journal; Patents and Inventions: DGM is a coinventor of the pending patent application “Methods and Systems for Diagnosis of Acute Interstitial Nephritis” that is subject to an option for a license agreement with Renalytix AI Inc.; Scientific Advisor or Membership: Kidney360, editorial board member. M. Perazella reports Royalties: as an Author for UpToDate; Participation on a Data Safety Monitoring Board or Advisory Board: DSMB for Yale study on HER alerts for AKI (no compensation).

Funding

None

Acknowledgements

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or Kidney360. Responsibility for the information and views expressed herein lies entirely with the author(s).

Author Contributions

D Moledina: Conceptualization; Writing - original draft; Writing - review and editing
M Perazella: Conceptualization; Supervision; Writing - original draft; Writing - review and editing

REFERENCES

Table 1. Specific Challenges to be addressed in Acute Interstitial Nephritis

<table>
<thead>
<tr>
<th>Clinical diagnostic challenges of AIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Utility of clinical features of immune and drug-induced causes of AIN</td>
</tr>
<tr>
<td>• Accuracy of currently available clinical features for AIN</td>
</tr>
<tr>
<td>• Accuracy of currently available blood tests for AIN</td>
</tr>
<tr>
<td>• Accuracy of currently available urinary tests for AIN</td>
</tr>
<tr>
<td>• The role of imaging tests</td>
</tr>
<tr>
<td>• The role of novel biomarkers</td>
</tr>
<tr>
<td>• Features that establish the diagnosis of AIN</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pathological diagnostic challenges of AIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Relevance of histological features such as inflammatory interstitial infiltrate (lymphocytes, eosinophils, plasma cells, etc.), tubulitis, and granuloma</td>
</tr>
<tr>
<td>• Relevance of associated diagnoses including acute tubular injury, glomerular diseases, and other pathology</td>
</tr>
<tr>
<td>• Utility of novel studies of the kidney tissue including T-cell subsets, mast cells, and macrophages</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prognosis and management challenges of AIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Accuracy of data in determining the prognosis of AIN</td>
</tr>
<tr>
<td>• Approach to identifying and discontinuing the offending agent in drug-induced AIN</td>
</tr>
<tr>
<td>• Appropriate use of corticosteroids in the treatment of AIN</td>
</tr>
<tr>
<td>o Intravenous vs. oral corticosteroids to initially treat AIN</td>
</tr>
<tr>
<td>o Oral steroids alone to treat AIN</td>
</tr>
<tr>
<td>o Combination of intravenous and oral corticosteroids to treat AIN</td>
</tr>
<tr>
<td>• Appropriate duration of corticosteroid therapy for AIN</td>
</tr>
<tr>
<td>• Appropriate discontinuation and tapering of corticosteroids prior to reaching the intended duration</td>
</tr>
<tr>
<td>• Utility of other drugs appropriate for the treatment of AIN (e.g., mycohenolic acid, azathioprine, etc.)</td>
</tr>
<tr>
<td>• Utility of potential novel, targeted therapies to treat AIN (anti-TNFα drugs, antihistamines, etc.)</td>
</tr>
</tbody>
</table>
Legend

Figure 1. Clinical and histopathological diagnosis and therapy of AIN. Clinical symptoms and signs, laboratory and imaging tests are sometimes useful to make a diagnosis of AIN. However, histopathology obtained through kidney biopsy is frequently required to make a diagnosis of AIN and ultimately guide management. Abbreviations: acute interstitial nephritis, AIN.
Histopathological diagnosis

Inflammatory infiltrate
- T cells, eosinophils
- Mast cells, other
- Tubulitis, granuloma
- Interstitial edema/fibrosis
- Acute tubular injury

Clinical/laboratory diagnosis

Rash, fever, flank pain
Eosinophilia
Sterile pyuria
Leukocyte casts
Eosinophiluria
Urinary biomarkers

Prognosis and treatment

Identify drug or cause
IV/oral corticosteroids vs. supportive care
Mycophenolic acid
Other agents?